Andrea Matthews - 17 Apr 2023 Form 3 Insider Report for Astria Therapeutics, Inc. (ATXS)

Role
Chief Business Officer
Signature
/s/ Ben Harshbarger, as attorney-in-fact for Andrea Matthews
Issuer symbol
ATXS
Transactions as of
17 Apr 2023
Net transactions value
$0
Form type
3
Filing time
19 Apr 2023, 08:09:00 UTC
Next filing
06 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATXS Stock Option (Right to Buy) 17 Apr 2023 Common Stock 389 $432.00 Direct F1
holding ATXS Stock Option (Right to Buy) 17 Apr 2023 Common Stock 51 $663.00 Direct F1
holding ATXS Stock Option (Right to Buy) 17 Apr 2023 Common Stock 166 $274.20 Direct F1
holding ATXS Stock Option (Right to Buy) 17 Apr 2023 Common Stock 250 $258.60 Direct F1
holding ATXS Stock Option (Right to Buy) 17 Apr 2023 Common Stock 183 $74.40 Direct F1
holding ATXS Stock Option (Right to Buy) 17 Apr 2023 Common Stock 83 $76.20 Direct F1
holding ATXS Stock Option (Right to Buy) 17 Apr 2023 Common Stock 416 $76.80 Direct F1
holding ATXS Stock Option (Right to Buy) 17 Apr 2023 Common Stock 833 $42.60 Direct F1
holding ATXS Stock Option (Right to Buy) 17 Apr 2023 Common Stock 2,083 $26.34 Direct F1
holding ATXS Stock Option (Right to Buy) 17 Apr 2023 Common Stock 3,333 $31.92 Direct F2
holding ATXS Stock Option (Right to Buy) 17 Apr 2023 Common Stock 4,166 $39.78 Direct F3
holding ATXS Stock Option (Right to Buy) 17 Apr 2023 Common Stock 66,666 $17.22 Direct F4
holding ATXS Stock Option (Right to Buy) 17 Apr 2023 Common Stock 32,812 $6.51 Direct F5
holding ATXS Stock Option (Right to Buy) 17 Apr 2023 Common Stock 60,000 $13.36 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested.
F2 This option was granted February 12, 2020 and is subject to vesting over a four-year period, with 25% of the 3,033 shares underlying the option upon grant vesting on the first anniversary of February 12, 2020 and the remainder vesting over the ensuing three years in equal monthly installments.
F3 This option was granted October 7, 2020 and is subject to vesting over a four-year period, with 25% of the 4,166 shares underlying the option upon grant vesting on the first anniversary of October 7, 2020 and the remainder vesting over the ensuing three years in equal monthly installments.
F4 This option was granted April 1, 2021 and is subject to vesting over a four-year period, with 25% of the 66,666 shares underlying the option upon grant vesting on the first anniversary of April 1, 2021 and the remainder vesting over the ensuing three years in equal monthly installments.
F5 This option was granted March 1, 2022 and is subject to vesting over a four-year period, with 25% of the 45,000 shares underlying the option upon grant vesting on the first anniversary of February 17, 2022 and the remainder vesting over the ensuing three years in equal monthly installments.
F6 This option was granted February 1, 2023 and is subject to vesting over a four-year period, with 25% of the 60,000 shares underlying the option upon grant vesting on the first anniversary of February 1, 2023 and the remainder vesting over the ensuing three years in equal monthly installments.

Remarks:

Exhibit Index: 24 - Power of Attorney; No securities are beneficially owned.